By Sapna 
Suraksha Diagnostic IPO is set to open for subscription on November 29, 2024, and will close on December 3, 2024. The Kolkata-based diagnostic service provider aims to raise up to ₹846.25 crore through an Offer for Sale (OFS) of approximately 19.1 million shares. The price band for the IPO has been set between ₹420 and ₹441 per share. Investors can apply in lots of 34 shares and multiples thereof
Company Overview:
Founded in 2005, Suraksha Diagnostic offers a comprehensive range of diagnostic services, including pathology, radiology, and medical consultations. It operates over 215 touchpoints across regions like West Bengal, Bihar, Assam, and Meghalaya. The company has a strong technological infrastructure, including digital pathology and advanced MRI and CT scan facilities
Grey Market Premium (GMP):
As of the latest updates, Suraksha Diagnostic’s Grey Market Premium (GMP) is estimated at around ₹30-40 per share, indicating positive sentiment among investors. GMP reflects the premium investors are willing to pay over the IPO price in the unofficial market and is often seen as an indicator of expected listing performance
Investment Considerations:
- Strengths: Suraksha Diagnostic’s leadership position in Eastern India, robust financials, and focus on digital health solutions make it a strong contender in the diagnostics market.
- Risks: The IPO is entirely an OFS, meaning the proceeds will go to existing shareholders, not the company. Additionally, GMP is volatile and can change based on market sentiment and demandBusiness TodayMoney Mint idea.
Conclusion:
For investors, the IPO presents an opportunity to invest in a growing diagnostics brand, though risks associated with market conditions and the offer structure should be considered. Those interested in short-term gains may find the GMP insights valuable, while long-term investors might focus on the company’s strategic positioning and growth potential.